by EpicentRx | Sep 15, 2022 | Conferences
July 2022, San Diego, California Poster: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model...
by EpicentRx | Sep 14, 2022 | Blog
Two famous quotes attributed to the Great One, ice hockey legend Wayne Gretzky, “I skate to where the puck is going, not where it has been,” and “you miss 100% of the shots you never take,” perfectly encapsulate the corporate strategy at EpicentRx. This strategy is,...
by EpicentRx | Sep 9, 2022 | Blog
With apologies to Toy Story’s Buzz Lightyear for borrowing his “To Infinity and Beyond” catchphrase, EpicentRx has developed and manufactured a Nucleocapsid vaccine, N-finity or N-VAX, for COVID-19, which has the potential to universally protect against all current...
by EpicentRx | Aug 30, 2022 | Media
EpicentRx used its AdAPT Platform to develop a nucleocapsid-based next-gen COVID 19 vaccine candidate and is ready for clinical trials. CEO Dr. Tony Reid recently discussed with Drug Discovery & Development.
by EpicentRx | Aug 10, 2022 | Blog
As doctors, we were on the back nine last weekend, working on our slice, and it occurred to us that a good name for a golf magazine, should we ever decide to write one, in all our free time, (snort), is “Of course!” No eye rolling please, c’mon, it’s a legit name....
